A special kind of immune cell serves as an intermediary between gut bacteria and the brain, according to Susanne Wolf from Max Delbruck Centre for Molecular Medicine in Germany.
The findings are of significance when it comes to the effects of using antibiotics in the long term, and could also help to alleviate the symptoms of mental disorders, researchers said.
The gut and the brain "talk" to one another via hormones, metabolic products or direct neural connections. A specific population of monocyte immune cells acts as a further link between the two, they said.
Compared to the mice that had not undergone treatment, they subsequently observed significantly fewer newly formed nerve cells in the hippocampus region of the brain.
The memory of the treated mice also deteriorated because the formation of these new brain cells - a process known as neurogenesis - is important for certain memory functions.
As well as impaired neurogenesis, researchers also found that the population of a specific immune cell in the brain - the Ly6C(hi) monocytes - decreased significantly when the microbiota was switched off.
They cured the antibiotic-treated mice using two different strategies - the mice were either given a mixture of selected bacterial strains or had access to voluntary training in the running wheel, thus reversing the negative effects of the antibiotics.
The mice's number of monocytes increased and their memory performance and neurogenesis improved. However, it was not possible to restore the immune and brain functions using the microbiota of untreated mice, researchers said.
Applied to humans, the findings do not show that all antibiotics disrupt brain function, as the combination of drugs used in the study was extremely potent, researchers said.
"It is possible, however, that similar effects could result from treatments involving long-term use of antibiotics," said Wolf.
Researchers also found that the antibiotics may affect neurogenesis directly, and not act only via the gut bacteria.
The study is also of significance for treating people with mental disorders such as schizophrenia or depression, who also have impaired neurogenesis, said Wolf.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
